Loading...
XNAS
PRPH
Market cap5mUSD
Dec 05, Last price  
0.13USD
1D
-7.14%
1Q
-63.37%
Name

Prophase Labs Inc

Chart & Performance

D1W1MN
XNAS:PRPH chart
P/E
—
P/S
0.86
EPS
—
Div Yield, %
—
Shrs. gr., 5y
10.53%
Rev. gr., 5y
-7.27%
Revenues
7m
-84.75%
53,658,04342,124,96939,475,38120,506,61219,816,00014,502,00017,453,00022,406,00025,032,00022,070,00020,604,00021,014,0009,867,00013,126,0009,876,00014,514,00079,042,000122,647,00044,384,0006,770,000
Net income
-53m
L+217.98%
3,216,684-1,748,345-2,458,337-5,534,286-3,842,000-3,501,000-2,710,000-1,091,000405,000-7,834,000-3,600,000-2,868,00041,831,000-1,740,000-3,013,000-2,420,0006,273,00018,463,000-16,782,000-53,364,000
CFO
-18m
L+54.55%
4,265,489956,943-1,311,598-3,057,592445,000-3,549,000-2,108,000-5,729,0001,137,000-3,216,000-3,497,000-472,000-2,838,000-2,119,000-841,000-2,592,000-13,619,00028,551,000-11,348,000-17,538,000
Dividend
May 24, 20220.3 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements in the United States. The company operates in two segments, Diagnostic Services and Consumer Products. It offers a range of OTC dietary supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. The company also provides contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; SARS-CoV-2 (COVID-19) and COVID-19 viral mutation polymerase chain reaction tests through saliva and nasal swab methods; and other respiratory pathogen panel molecular testing services, as well as personal genomics products and services. It serves national chain drug, internet-based, and various regional retailers. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.
URL
https://www.prophaselabs.com/
IPO date
Jan 16, 1984
Employees
129
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT